Literature DB >> 11179124

Susceptibility genes for rapid decline of lung function in the lung health study.

A J Sandford1, T Chagani, T D Weir, J E Connett, N R Anthonisen, P D Paré.   

Abstract

The genes that contribute to the genetic susceptibility to chronic obstructive pulmonary disease (COPD) remain largely unknown. We hypothesized that widely divergent rates of decline in lung function in smokers would be a robust phenotype for detection of genes that contribute to COPD severity. We selected 283 rapid decliners (deltaFEV1 = -154 +/- 3 ml/yr) and 308 nondecliners (deltaFEV1 = +15 +/- 2 ml/yr) from among smokers followed for 5 yr in the NHLBI Lung Health Study. Rapid decline of FEV1 was associated with the MZ genotype of the alpha1-antitrypsin gene (odds ratio [OR] = 2.8, p = 0.03). This association was stronger for a combination of a family history of COPD with MZ (OR = 9.7, p = 0.03). These data suggest that the MZ genotype results in an increased rate of decline in lung function and interacts with other familial factors. Haplotype frequencies of the microsomal epoxide hydrolase (mEH) gene were significantly different between rapid decliners and nondecliners (p = 0.03). A combination of a family history of COPD with homozygosity for the His113/His139 mEH haplotype was also associated with rapid decline of lung function (OR = 4.9, p = 0.04). The alpha1-antitrypsin S and 3' polymorphisms, vitamin D-binding protein isoforms, and tumor necrosis factor (TNF-alpha G-308A and TNF-beta A252G) polymorphisms were not associated with rate of decline of lung function.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179124     DOI: 10.1164/ajrccm.163.2.2006158

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  65 in total

Review 1.  Inhaled steroids for COPD?

Authors:  A E Tattersfield; T W Harrison
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Passive smoking and lung function in alpha(1)-antitrypsin heterozygote schoolchildren.

Authors:  G M Corbo; F Forastiere; N Agabiti; V Dell'Orco; R Pistelli; G Massi; C A Perucci; S Valente
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

3.  Heme oxygenase-1 gene promoter polymorphism and decline in lung function in Japanese men.

Authors:  K Nakayama; A Kikuchi; H Yasuda; S Ebihara; T Sasaki; T Ebihara; M Yamaya
Journal:  Thorax       Date:  2006-10       Impact factor: 9.139

Review 4.  Progress in chronic obstructive pulmonary disease genetics.

Authors:  Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2006-07

Review 5.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  Can Respir J       Date:  2007-10       Impact factor: 2.409

Review 6.  Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis.

Authors:  J Gao; G Shan; B Sun; P J Thompson; X Gao
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

7.  Variability in small airway epithelial gene expression among normal smokers.

Authors:  Zeinab Ammous; Neil R Hackett; Marcus W Butler; Tina Raman; Igor Dolgalev; Timothy P O'Connor; Ben-Gary Harvey; Ronald G Crystal
Journal:  Chest       Date:  2008-03-13       Impact factor: 9.410

8.  Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations.

Authors:  Craig P Hersh; Dawn L Demeo; Christoph Lange; Augusto A Litonjua; John J Reilly; David Kwiatkowski; Nan Laird; Jody S Sylvia; David Sparrow; Frank E Speizer; Scott T Weiss; Edwin K Silverman
Journal:  Am J Respir Cell Mol Biol       Date:  2005-04-07       Impact factor: 6.914

Review 9.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

10.  Association of the tumor necrosis factor-alpha -308 G/A polymorphism with nasal polyposis.

Authors:  Hunkar Batikhan; Mustafa Kursat Gokcan; Esen Beder; Nejat Akar; Aysenur Ozturk; Muharrem Gerceker
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-11       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.